Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225418 | 0.86 | BRD4 (0.55) | BRD4KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL19459408 | 0.84 | KCNK3 (0.47) | BRD4KMT2AHTTADORA3ADORA2A | |
| SCHEMBL3739876 | 0.84 | BRD4 (0.53) | BRD4KMT2AKDM4EALDH1A1MAPK1 | |
| SCHEMBL8493065 | 0.84 | ALDH1A1 (0.59) | BRD4KMT2AHTTKDM4EALDH1A1 | |
| SCHEMBL28046011 | 0.83 | ALDH1A1 (0.55) | BRD4KMT2AHTTMEN1ALDH1A1 | |
| SCHEMBL171580 | 0.83 | KMT2A (0.70) | BRD4KMT2AHTTMEN1KDM4E | |
| SCHEMBL30356246 | 0.83 | KMT2A (0.70) | BRD4KMT2AHTTMEN1KDM4E | |
| SCHEMBL14046286 | 0.82 | ALDH1A1 (0.61) | KMT2AMEN1KDM4EALDH1A1MAPK1 | |
| SCHEMBL10874427 | 0.82 | KMT2A (0.51) | BRD4KMT2AHTTMEN1KDM4E | |
| SCHEMBL1141399 | 0.82 | P2RX7 (0.53) | BRD4KMT2AHTTMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108727307-A | Compound and its application method | 安吉奥斯医药品有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-104936954-B | Compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2018-08-14 | — | — | CN | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-6750349-B2 | SUPERIOR GASTROKINETIC PROPERTIES | JANSSEN PHARMACEUTICS, N.V. (BE) | 2004-06-15 | — | — | US | disclosed |
| EP-1000028-B1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-04-24 | — | — | US | disclosed |
| US-6452013-B1 | FOR TREATING CONDITIONS WHICH ARE RELATED TO IMPAIRMENT OF GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-17 | — | — | US | disclosed |
| EP-0880500-B1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-07-31 | — | — | EP | disclosed |
| CN-1297442-A | 5-aminoindeno [1,2-c] pyrazol-4-ones as anti-cancer and anti-proliferative agents | DU PONT PHARM CO (US) | 2001-05-30 | — | — | CN | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-6096761-A | REACTING A N-SUBSTITUTED 4-METHANOL-3-HYDROXY OR ALKOXY-PIPERIDINE INTERMEDIATE WITH A CARBOXYLIC ACID DERIVATIVES; ADMINISTERING TO AN ANIMAL SUFFERING WITH A CONDITION RELATED TO HAMPERED OR IMPAIRED GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-08-01 | — | — | US | disclosed |
| EP-1000028-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| WO-1999002494-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0880500-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| EP-0862560-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997030031-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997019065-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| WO-1995030651-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, ALK, CBR1 | BRD4 2338/4885KMT2A 2566/4885HTT 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.